Secondary prevention of deep vein thrombosis: current approaches, efficacy and safety

Background: Deep vein thrombosis (DVT) is one of the most significant vascular diseases, often complicated by pulmonary embolism (PE). The high risk of recurrent DVT requires long-term secondary prevention, which dictates the need to select optimal anticoagulant therapy and continuously assess the balance between efficacy and safety.

Objective: Review of current strategies for secondary prevention of DVT, assessment of the risks and benefits of prolonged anticoagulant therapy, with an emphasis on the role of new direct oral anticoagulants (DOACs), in particular rivaroxaban and its generic Xyltess.

Results: An analytical review of current international and domestic clinical guidelines, as well as key prospective studies on secondary prevention of venous thromboembolic complications (VTEC) was conducted. Prolonged DOAC therapy showed the greatest effectiveness in preventing recurrent DVT and other VTEC. Idiopathic DVT, thrombophilia, proximal localization and concomitant oncology require an individualized approach to the duration of therapy. The generic drug rivaroxaban Xyltess is completely bioequivalent to the original, has European quality and improved accessibility for patients.

Conclusion: Prolonged secondary prevention of DVT using modern DOACs allows achieving an optimal balance of benefit and safety, reducing the risk of relapse and improving long-term clinical outcomes in most categories of patients.